Omhyggelig monitorering af pædiatriske patienter er specielt berettiget, særligt i de første 18 uger af behandlingen, da disse patienter formodentlig i mindre grad end voksne bemærker eller rapporterer hudreaktioner.
Careful monitoring of paediatric patients is especially warranted, particularly in the first 18 weeks of treatment, since these patients may be less likely than adults to notice, or report, skin reactions.